LabCorp
LH
$312.15
-0.65%
Labcorp Holdings Inc. is one of the nation's two largest independent clinical laboratory operators, running roughly 2,000 patient-service centers and offering a portfolio of approximately 5,000 clinical tests spanning routine blood and urine screens to complex oncology and genomic diagnostics, organized across its Labcorp Diagnostics and Biopharma Laboratory Services segments. As a duopoly participant alongside Quest Diagnostics with roughly 20% of the independent lab market, Labcorp's competitive identity rests on unrivaled scale in routine testing, deep payer and health-system relationships, and an increasingly differentiated biopharma clinical-trials franchise that provides a higher-growth, higher-margin counterweight to its core diagnostics business. The current investor narrative centers on the company's AI and robotics investments, which management credits with driving operational efficiency and margin improvement, alongside a strong Q1 2026 earnings beat and raised full-year guidance that lifted sentiment through mid-year. That optimism has been partially tempered by reimbursement-policy anxiety, with a September 2026 selloff attributed to fears over potential Medicare rate cuts, leaving investors debating whether the pullback already discounts worst-case pricing outcomes or whether structural margin risk remains underpriced.…
LH
LabCorp
$312.15
Related headlines
Investment Opinion: Should I buy LH Today?
The synthesized recommendation is Buy, anchored by a consensus analyst rating of 'buy' (mean 1.72) and an average target price of $345.13, implying 10.6% upside. The core thesis is that Labcorp offers a defensive, cash-generative healthcare compounder with accelerating revenue growth and a discounted forward valuation, while the recent reimbursement-driven selloff has created an attractive entry point for long-term investors.
Supporting evidence includes: 1) Q2 2026 revenue growth of 5.78% year-over-year, the strongest in recent quarters; 2) a forward PE of 15.78x, which is 34% below the trailing PE and below many healthcare-services peers; 3) trailing-twelve-month free cash flow of $1.155 billion, funding both buybacks and dividends; and 4) a dividend yield of 1.15% with a conservative 27.5% payout ratio. The stock also trades at a discount to the sector on forward earnings despite its scale advantages.
The biggest risks that could invalidate the thesis are: 1) deeper-than-expected Medicare reimbursement cuts that compress margins; 2) a slowdown in biopharma segment growth or loss of major contracts; and 3) valuation compression if earnings fail to meet the implied growth. The rating would upgrade to a stronger Buy if the forward PE compresses below 14x or if reimbursement uncertainty resolves favorably, and it would downgrade to Hold if revenue growth decelerates below 3% or if net margin falls below 5%. Relative to its history and peers, the stock appears fairly valued on trailing metrics but undervalued on forward earnings, offering a balanced risk/reward for patient investors.
Sign up to view all
LH 12-Month Price Forecast
Labcorp presents a balanced risk/reward profile, with the bull case supported by accelerating revenue, strong cash flow, and a discounted forward valuation, while the bear case is anchored by reimbursement policy risk and moderate leverage. The analyst consensus is constructive, but the recent pullback reflects genuine uncertainty. I would upgrade to bullish if reimbursement concerns are resolved favorably or if the forward PE remains below 16x with continued earnings beats; I would downgrade to bearish if Medicare rate cuts are enacted or if revenue growth decelerates below 3%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LabCorp's 12-month outlook, with a consensus price target around $345.13 and implied upside of +10.6% versus the current price.
Average Target
$345.13
0 analysts
Implied Upside
+10.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$293 - $385
Analyst target range
Coverage is robust, with 16 analysts following Labcorp and a consensus recommendation of "buy" (recommendation mean of 1.72 on a scale where 1 is strong buy). The average price target of $345.13 implies roughly 10.6% upside from the current price of $312.15, a constructive but not aggressive signal that suggests analysts see solid value with the stock having already rallied substantially year-to-date. The consensus leans bullish, supported by a steady stream of reaffirmed positive ratings — Truist Securities and UBS both maintained Buy ratings in September 2026, JP Morgan and Morgan Stanley reiterated Overweight in late July and early August, and B of A Securities and Baird kept Buy/Outperform ratings in July. The absence of downgrades in the institutional ratings data, despite the September reimbursement-driven selloff, indicates analysts view the pullback as a buying opportunity rather than a fundamental deterioration. The target range spans $293.00 to $385.00, a spread of roughly 31% of the current price that signals meaningful disagreement about the company's trajectory. The high target of $385 implies about 23.4% upside and likely assumes successful AI-driven margin expansion, continued mid-single-digit revenue growth, multiple expansion toward the upper end of the historical band, and resolution of reimbursement uncertainty in the company's favor. The low target of $293 sits about 6.1% below the current price and likely prices in Medicare reimbursement cuts, margin compression from pricing pressure, and a more cautious volume outlook. The relatively tight clustering of the average target around $345, combined with the fact that the low target is only modestly below the current price, suggests analysts have reasonably high conviction that downside is limited — a constructive setup for investors willing to look through near-term reimbursement noise toward the company's steady growth and cash-generation profile.
Bulls vs Bears: LH Investment Factors
The bull case currently has stronger evidence, supported by accelerating revenue growth, a discounted forward PE, robust free cash flow, and a bullish analyst consensus. However, the bear case is anchored by real reimbursement-policy anxiety that triggered a September selloff and could structurally pressure margins. The single most important tension is whether the market has fully priced in potential Medicare rate cuts or if further downside remains; resolution of this policy uncertainty will likely determine whether the stock re-rates toward the high target or retests the low end of the range.
Bullish
- Revenue growth accelerating: Q2 2026 revenue of $3.731 billion grew 5.78% year-over-year, the strongest absolute quarter in the trailing six periods and a clear acceleration from the roughly 1-2% sequential pace seen earlier. This top-line momentum, combined with raised full-year guidance, supports a durable growth narrative.
- Forward PE implies earnings surge: The forward PE of 15.78x is 34% below the trailing PE of 23.80x, implying analysts expect EPS to jump to $25.57 from the current run-rate. This compression signals the market is pricing in significant earnings expansion driven by margin improvement and buybacks.
- Strong free cash flow and capital returns: Trailing-twelve-month free cash flow is $1.155 billion, with Q2 2026 alone generating $313.9 million. The company returned $353.8 million via buybacks and $58.7 million in dividends in the quarter, demonstrating robust cash generation and shareholder-friendly capital allocation.
- Analyst consensus bullish with upside: 16 analysts rate the stock a 'buy' with a mean recommendation of 1.72, and the average target price of $345.13 implies 10.6% upside. The absence of downgrades despite a September reimbursement-driven selloff suggests analysts view the pullback as a buying opportunity.
Bearish
- Reimbursement policy overhang: A September 2026 selloff was attributed to fears over potential Medicare rate cuts, highlighting structural margin risk. With roughly 78% of revenue from Labcorp Diagnostics, any adverse pricing decision could disproportionately impact profitability.
- Recent momentum deceleration: The 1-month change is -2.79% and the stock trails SPY by 4.91 percentage points over the past month, signaling a short-term pullback. This divergence from the positive 1-year trend (up 12.37%) suggests waning near-term momentum.
- Modest net margin and high debt: Net margin is only 6.28% and debt-to-equity stands at 0.836, indicating a capital-intensive business with moderate leverage. The Q2 net cash decline of $839.3 million, driven by $475 million of debt repayment, constrains balance-sheet flexibility.
- Valuation not cheap on trailing basis: The trailing PE of 23.80x sits in the middle-to-upper portion of the post-pandemic range, and the PEG ratio of 1.28 is above 1.0. This suggests the stock is priced roughly in line with growth, leaving little room for error.
LH Technical Analysis
Labcorp is in a sustained uptrend, with the shares up 12.37% over the past year and 24.04% year-to-date, and the current price of $312.15 sits at roughly 69.6% of the 52-week range between a low of $244.52 and a high of $341.80. That positioning — well above the midpoint but still about 8.7% below the 52-week high — suggests a stock with positive momentum that has cooled from its peak rather than one that is either overextended at highs or languishing near lows. The 6-month gain of 19.63% confirms the intermediate trend remains constructive even after the recent consolidation. Recent momentum has decelerated sharply, however: the 1-month change is -2.79% and the 3-month change is +12.77%, meaning the stock has given back ground after a strong summer run. This divergence between a positive 1-year trend and a negative 1-month reading signals a temporary pullback or mean-reversion phase rather than a confirmed reversal, particularly since the stock is still up double digits over three months. Relative strength versus the S&P 500 tells the same story — LH trails SPY by 4.91 percentage points over the past month but leads by 9.64 points over three months and 9.87 points year-to-date, indicating the recent weakness is a short-term underperformance blip within a longer stretch of market outperformance. Key technical levels are well defined: the 52-week high at $341.80 is the primary resistance zone, and a breakout above it would confirm renewed leadership and likely draw momentum buyers, while the 52-week low at $244.52 represents major support roughly 21.7% below the current price. A breakdown below the recent $304-$306 area (the early-October lows) would put the September 10 intraday weakness near $306.96 in play and could open a deeper retest toward the low-$300s. With a beta of 0.846, Labcorp is roughly 15% less volatile than the broader market, which supports smaller position-sizing adjustments for risk and suggests the stock is more of a defensive compounder than a high-beta trading vehicle; the maximum drawdown of -15.22% over the period reinforces that downside has been relatively contained.
Beta
0.85
0.85x market volatility
Max Drawdown
-15.2%
Largest decline past year
52-Week Range
$245-$342
Price range past year
Annual Return
+12.4%
Cumulative gain past year
| Period | LH Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | +1.9% |
| 3m | +12.8% | +3.9% |
| 6m | +19.6% | +12.1% |
| 1y | +12.4% | +19.2% |
| ytd | +24.0% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LH Fundamental Analysis
Labcorp's revenue trajectory is steadily growing, with Q2 2026 revenue of $3.731 billion representing 5.78% year-over-year growth versus Q2 2025's $3.527 billion. The multi-quarter trend shows consistent sequential expansion — from $3.345 billion in Q1 2025 to $3.528 billion in Q2 2025, $3.564 billion in Q3 2025, $3.516 billion in Q4 2025, $3.538 billion in Q1 2026, and $3.731 billion in Q2 2026 — with the most recent quarter marking the strongest absolute level and a clear acceleration from the roughly 1-2% sequential pace seen earlier. Segment data shows Labcorp Diagnostics contributing $2.901 billion and Biopharma Laboratory Services adding $836.2 million, meaning the core diagnostics franchise remains the dominant revenue engine at roughly 78% of the total while biopharma provides the growth optionality. This steady mid-single-digit top-line growth, combined with raised guidance, supports an investment case built on durable volume growth, pricing discipline, and mix shift toward higher-value esoteric testing rather than cyclical or acquisition-driven expansion. Profitability is solid and improving: Q2 2026 net income was $298.7 million on a 29.8% gross margin, with net margin of 8.01% and operating margin of 12.10%. The margin trajectory has been choppy but upward — gross margin moved from 26.52% in Q1 2026 to 29.80% in Q2 2026, and net income rose from $277.8 million to $298.7 million over the same span, while the year-ago Q2 2025 net income was $237.9 million on a 29.66% gross margin. The improvement in net income year-over-year despite a roughly flat gross margin reflects operating leverage and cost discipline, consistent with management's emphasis on AI and robotics-driven efficiency; the 10.87% operating margin and 6.28% net margin are respectable for a capital-intensive diagnostics business where scale economics matter enormously. Balance sheet health is adequate but not fortress-like: debt-to-equity stands at 0.836, the current ratio is 1.42, and ROE is 10.17% with ROA of 5.53%. Free cash flow on a trailing-twelve-month basis is $1.155 billion, and Q2 2026 alone generated $313.9 million of FCF on $445.5 million of operating cash flow against $131.6 million of capex, while the company returned capital via $353.8 million of buybacks and $58.7 million of dividends in the quarter. The company funds growth internally and still returns cash, but the Q2 net cash decline of $839.3 million — driven by $475 million of debt repayment and $225.7 million of acquisitions — shows management is actively deleveraging and bolt-on acquiring, which modestly constrains near-term balance-sheet flexibility even as it supports the long-term growth algorithm.
Quarterly Revenue
$3.7B
2026-06
Revenue YoY Growth
+5.8%
YoY Comparison
Gross Margin
29.8%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LH Overvalued?
Because Labcorp is solidly profitable — Q2 2026 net income of $298.7 million and trailing EPS positive — the PE ratio is the appropriate primary metric, and the trailing PE of 23.80x against a forward PE of 15.78x implies the market expects meaningful earnings growth ahead. That 34% compression from trailing to forward multiple is a strong signal: analysts project EPS of $25.57 on average, and the gap suggests the market is pricing in double-digit earnings expansion driven by margin improvement, buybacks, and operating leverage rather than multiple expansion. The PEG ratio of 1.28 is modestly above 1.0, indicating the stock is priced roughly in line with its growth rate — not cheap, but not stretched for a defensive healthcare compounder. Relative to the broader healthcare and diagnostics sector, Labcorp screens as reasonably valued: its PS ratio of 1.50 and EV/Sales of 2.24 are low in absolute terms, while EV/EBITDA of 13.69x is a mid-teens multiple typical of mature lab-services peers. The forward PE of 15.78x is below the broader market and below many healthcare-services comparables, suggesting the stock trades at a discount to the sector on forward earnings despite its scale advantages and improving margins. The dividend yield of 1.15% with a conservative 27.5% payout ratio adds an income dimension without straining the capital-return program. Historically, Labcorp's PE has ranged widely — from roughly 10-12x in 2021-2022 when COVID testing inflated earnings, to the 20-33x range across 2024-2025 as the business normalized. The current trailing PE of 23.80x sits in the middle-to-upper portion of that post-pandemic band, while the forward PE of 15.78x is closer to the lower end of the historical range. The PB ratio of 2.42 is near the middle of its multi-year 1.6-2.7x band, suggesting the market is neither euphoric nor despondent about the franchise. Taken together, the valuation reflects a company that has normalized post-COVID, is delivering steady growth, and is priced for continued execution rather than heroic assumptions — leaving room for re-rating if margin expansion accelerates.
PE
23.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 10x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on Labcorp's moderate leverage and thin net margins. Debt-to-equity of 0.836 and a current ratio of 1.42 indicate adequate but not fortress-like liquidity, while the net margin of 6.28% leaves little cushion for unexpected cost increases. The Q2 2026 net cash decline of $839.3 million, driven by $475 million of debt repayment and $225.7 million of acquisitions, shows management is actively deleveraging and bolt-on acquiring, which modestly constrains near-term balance-sheet flexibility. Additionally, revenue concentration in Labcorp Diagnostics (roughly 78% of total) means any weakness in routine testing volumes or pricing could disproportionately impact overall results.
Market and competitive risks include valuation compression if growth slows, regulatory headwinds from Medicare reimbursement policy, and sector rotation. The trailing PE of 23.80x is in the middle-to-upper portion of its historical range, and the PEG ratio of 1.28 suggests the stock is not cheap; any earnings miss could trigger multiple contraction. The September 2026 selloff on reimbursement fears highlights the stock's sensitivity to policy news, and with a beta of 0.846, it is less volatile than the market but still exposed to broad healthcare sector sentiment. Competitive pressure from Quest Diagnostics and hospital-based labs could also limit pricing power.
The worst-case scenario would involve a combination of Medicare rate cuts, margin compression, and a slowdown in biopharma segment growth. In this scenario, the stock could retest its 52-week low of $244.52, representing a 21.7% decline from the current price of $312.15. The analyst low target of $293 implies a 6.1% downside, but a more severe outcome could push shares toward the low $240s if reimbursement cuts are deeper than expected and operating leverage reverses. Investors could lose approximately 22% from current levels in this adverse scenario.
FAQ
The most severe risk is reimbursement policy changes, particularly Medicare rate cuts, which could compress margins and reduce earnings; the September 2026 selloff highlighted this vulnerability. Financial risks include moderate leverage with a debt-to-equity of 0.836 and a net margin of only 6.28%, leaving little cushion for cost increases. Competitive risks stem from Quest Diagnostics and hospital-based labs, which could pressure pricing and volume. Macro risks include sector rotation away from healthcare and sensitivity to interest rates, though the low beta of 0.846 mitigates broad market volatility. Company-specific risks include integration challenges from acquisitions and dependence on the biopharma segment for growth.
The 12-month forecast includes a base case (55% probability) with a target range of $320-$350, assuming steady execution and no major policy shocks. The bull case (25% probability) targets $345-$385, driven by favorable reimbursement resolution and margin expansion. The bear case (20% probability) targets $244-$293, reflecting Medicare rate cuts and margin compression. The most likely scenario is the base case, with the key assumption being that revenue grows around 5% and operating margins remain near 12%. The analyst average target of $345.13 aligns with the base case, implying 10.6% upside.
LH appears fairly valued on a trailing basis with a PE of 23.80x, which sits in the middle-to-upper portion of its post-pandemic range. However, the forward PE of 15.78x is below the broader market and many healthcare-services peers, suggesting the stock is undervalued on forward earnings. The PEG ratio of 1.28 indicates the stock is priced roughly in line with its growth rate. The PS ratio of 1.50 and EV/EBITDA of 13.69x are typical for mature lab-services companies. Overall, the market is pricing in continued execution rather than heroic assumptions, leaving room for re-rating if margin expansion accelerates.
From a risk/reward perspective, LH offers a balanced proposition with approximately 10.6% upside to the analyst average target of $345.13, but downside risk to the 52-week low of $244.52 represents a 21.7% decline. The forward PE of 15.78x is attractive relative to the trailing PE of 23.80x, suggesting earnings growth is expected. However, the reimbursement policy overhang remains a significant risk that could cap upside. For long-term investors comfortable with policy uncertainty, the stock is a reasonable buy at current levels, especially given its defensive beta of 0.846 and strong free cash flow. Those seeking higher growth may find better opportunities elsewhere.
LH is more suitable for long-term investment given its defensive characteristics, low beta of 0.846, and steady cash generation. The stock offers a modest dividend yield of 1.15% and a conservative payout ratio of 27.5%, making it attractive for income-focused investors. Short-term trading is less appealing due to the recent momentum deceleration (1-month change of -2.79%) and policy overhang, which could cause volatility around reimbursement news. A suggested minimum holding period is 2-3 years to allow for the resolution of reimbursement uncertainty and the realization of earnings growth. The stock's maximum drawdown of -15.22% over the past period suggests relatively contained downside for long-term holders.